个人简介
2019年7月经中国海洋大学“青年英才工程”第二层次引进在中国海洋大学医药学院工作，研究方向为基于靶标的合理药物设计、合成及活性研究，包括选择性HDAC抑制剂，基于HDAC抑制剂抗肿瘤机制的多靶点小分子。近五年来，在J Med Chem, Eur Med Chem, Bioorg Med Chem, Adv Cancer Res.等杂志发表SCI论文32篇，申请专利9项，6项已被授权。主持和参与多项国家和省部级基金项目。
教育背景
2011.09~2016.06 山东大学 药物化学 博士
2007.09~2011.06 山东大学 药学 学士
工作经历
2019.07 ~至今 中国海洋大学医药学院 副教授
2016.08~2019.06 美国南卡罗来纳医科大学 博士后
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Xiaoyang Li#*, Yuqi Jiang#, Yuri K. Peterson, TongqiangXu, Richard A. Himes, Xin Luo, Guilin Yin, Elizabeth S. Inks, Nathan Dolloff, Stephanie Halene, Sherine S. L. Chan, and C. James Chou*.Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. J Med Chem. 2020, 28; 63(10):5501-5525.
Xiaoyang Li*, Richard A. Himes, Lyndsey C. Prosser, Charleston F. Christie, Emma Watt, Sharon F. Edwards, Cameron Metcalf, Peter West, Karen Wilcox, Sherine S. L. Chan*, and C. James Chou*. Discovery of the first Vitamin K analog as a potential treatment of pharmacoresistant seizures. J Med Chem. 2020 63(11):5865-5878.
Lihui Zhang#, Xiaoyang Li#, Yiming Chen, Minghui Wan, Qixiao Jiang, Li Zhang, C. James Chou, Weiguo Song and Lei Zhang*. Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino) Benzamide as a Potent Histone Deacetylase Inhibitor. Front Pharmacol.2019; 10: 957.
Xiaoyang Li, Yuri K. Peterson, Elizabeth S. Inks, Richard A. Himes,Jiaying Li,Yingjie Zhang, Xiujie Kong, and C. James Chou*.Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. J Med Chem. 2018; 61(6):2589-2603.
Xiaoyang Li#, Yingjie Zhang#*, Yuqi Jiang, Jingde Wu, Elizabeth S. Inks, C. James Chou, Shuai Gao, Jinning Hou, Qinge Ding, Jingyao Li, Xue Wang, Yongxue Huang, Wenfang Xu. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study. Eur J Med Chem.2017; 134:185-206.
Xiaoyang Li, Jinning Hou, Xiaoguang Li, Yuqi Jiang, Xueliang Liu, Weiwei Mu, YimingJin, Yingjie Zhang*, Wenfang Xu*. Development of 3-Hydroxy cinnamamide-Based HDAC Inhibitors with Potent in vitro and in vivo Anti-tumor Activity. Eur J Med Chem. 2015; 7:628-637.
Xiaoyang Li, Jingde Wu, Xiaoguang Li, Weiwei Mu, Xueliang Liu, YimingJin, Wenfang Xu, Yingjie Zhang*. Development of N-hydroxy benzamide derivatives with indole-containing cap group as histone deacetylases inhibitors. Bioorg Med Chem.2015; 23(19):6258-6270.
Xiaoyang Li, Elizabeth S. Inks, Xiaoguang Li,Jinning Hou,C. James Chou,Jian Zhang,Yuqi Jiang,Yingjie Zhang*, and Wenfang Xu*. Discovery of the first N-hydroxycinnamamide -based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.J Med Chem. 2014; 57(8):3324-3334.
Xiaoyang Li, Jian Zhang, YuanchaoXie, Yuqi Jiang, Zhang Yingjie* and Wenfang Xu*. Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr Drug Targets. 2014; 15(6):622-634.
Xiaoyang Li and Wenfang Xu*. HDAC1/3 dual selective inhibitors-new potential therapeutic agent in the treatment of cancer. Drug Discov Ther. 2014; 8(5):225-228.
Jesse J. McClure, Xiaoyang Li, C. James Chou*. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics. Adv Cancer Res.2018; 138: 183-211.
Yuqi Jiang, Xiaoyang Li, Jinning Hou, Yongxue Huang,Xuejian Wang, Yuping Jia,Qingwei Wang,Wenfang Xu,Jian Zhang,Yingjie Zhang*.Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. Eur J Med Chem.2018; 143: 334-347.
Xue Wang,Xiaoyang Li, Jingyao Li, Jinning Hou, Ying Qu, Chenggong Yu, Feng He, Wenfang Xu, Jingde Wu*. Design, synthesis, and preliminary bioactivity evaluation of N1 -hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors. Chem Biol Drug Des.2017; 89(1):38-46.
Shuai Gao, Xiaoyang Li, Jie Zang,Wenfang Xu*, Yingjie Zhang*. Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy. Anticancer Agents Me.2017; 17: 802-812.
Yuqi Jiang, Xiaoyang Li, Jinning Hou,Yongxue Huang,Yuping Jia,Mingming Zou,Jian Zhang,Xuejian Wang,Wenfang Xu*,Yingjie Zhang*. Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent. Eur J Med Chem.2016; 121:649-57.
Jingyao Li, Xiaoyang Li, Xue Wang, Jinning Hou, Jie Zang, Shuai Gao, Wenfang Xu*,Yingjie Zhang*. PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors. Chem Biol Drug Des.2016; 88(4):574-584.
Yuqi Jiang, Xiaoyang Li, Xue Wang, Zhonglan Wang, Jian Zhang, Jingde Wu, Wenfang Xu*. Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents. Chem Biol Drug Des.2016; 88(4):542-555.
Jian Zhang, Xiaoyang Li, Yuqi Jiang, Jinhong Feng, Xiaoguang Li, Yingjie Zhang and Wenfang Xu*. Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino) proline peptidomimetics as matrix metalloproteinase inhibitors. Bioorg Med Chem. 2014; 22(11):3055-3064.
Xuewu Liang, Jie Zang, Xiaoyang Li, Shuai Tang, Min Huang, MeiyuGeng, C. James Chou, Chunpu Li, Yichun Cao, Wenfang Xu, Hong Liu,*, and Yingjie Zhang*. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. J. Med. Chem. 2019, 62, 3898−3923.
Yuqi Jiang, Xiaogang Li, Xiaoyang Li, Jinning Hou, Yongzheng Ding, Jian Zhang, Wenfang Xu, Yingjie Zhang*. Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU. Med Chem.2016; 12(1):30-6.
京公网安备 11010802027423号